Omega Therapeutics Inc. (OMGA)
Omega Therapeutics Statistics
Share Statistics
Omega Therapeutics has 55.37M shares outstanding. The number of shares has increased by 0.38% in one year.
| Shares Outstanding | 55.37M |
| Shares Change (YoY) | 0.38% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 87.56% |
| Shares Floating | 21.73M |
| Failed to Deliver (FTD) Shares | 431.1K |
| FTD / Avg. Volume | 4.5% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.67 and the forward PE ratio is null. Omega Therapeutics's PEG ratio is 0.11.
| PE Ratio | -1.67 |
| Forward PE | n/a |
| PS Ratio | 52.54 |
| Forward PS | 0.8 |
| PB Ratio | 2.8 |
| P/FCF Ratio | -1.72 |
| PEG Ratio | 0.11 |
Enterprise Valuation
Omega Therapeutics has an Enterprise Value (EV) of 222.56M.
| EV / Sales | 71.93 |
| EV / EBITDA | -2.38 |
| EV / EBIT | -2.43 |
| EV / FCF | -2.36 |
Financial Position
The company has a current ratio of 3.35, with a Debt / Equity ratio of 2.21.
| Current Ratio | 3.35 |
| Quick Ratio | 3.34 |
| Debt / Equity | 2.21 |
| Debt / EBITDA | -1.37 |
| Debt / FCF | -1.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -167.93% and Return on Invested Capital is -51.99%.
| Return on Equity | -167.93% |
| Return on Assets | -47.67% |
| Return on Invested Capital | -51.99% |
| Revenue Per Employee | $33.27K |
| Profits Per Employee | $-1.05M |
| Employee Count | 93 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 217.39 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -94.02% in the last 52 weeks. The beta is 1.64, so Omega Therapeutics's price volatility has been higher than the market average.
| Beta | 1.64 |
| 52-Week Price Change | -94.02% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | 1.09 |
| Relative Strength Index (RSI) | 29.48 |
| Average Volume (20 Days) | 9.59M |
Income Statement
In the last 12 months, Omega Therapeutics had revenue of 3.09M and earned -97.43M in profits. Earnings per share was -1.8.
| Revenue | 3.09M |
| Gross Profit | -62.77M |
| Operating Income | -100.26M |
| Net Income | -97.43M |
| EBITDA | -93.49M |
| EBIT | -100.26M |
| Earnings Per Share (EPS) | -1.8 |
Balance Sheet
The company has 68.44M in cash and 128.43M in debt, giving a net cash position of -59.98M.
| Cash & Cash Equivalents | 68.44M |
| Total Debt | 128.43M |
| Net Cash | -59.98M |
| Retained Earnings | -334.63M |
| Total Assets | 152.73M |
| Working Capital | 14.78M |
Cash Flow
In the last 12 months, operating cash flow was -91.51M and capital expenditures -2.87M, giving a free cash flow of -94.38M.
| Operating Cash Flow | -91.51M |
| Capital Expenditures | -2.87M |
| Free Cash Flow | -94.38M |
| FCF Per Share | -1.75 |
Margins
Gross margin is -2028.93%, with operating and profit margins of -3240.5% and -3148.93%.
| Gross Margin | -2028.93% |
| Operating Margin | -3240.5% |
| Pretax Margin | -3148.93% |
| Profit Margin | -3148.93% |
| EBITDA Margin | -3021.65% |
| EBIT Margin | -3240.5% |
| FCF Margin | -3050.39% |
Dividends & Yields
OMGA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -59.93% |
| FCF Yield | -58.05% |
Analyst Forecast
The average price target for OMGA is $12, which is 8471.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 8471.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -4.93 |
| Piotroski F-Score | 4 |